Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Correspondence] Corticosteroid therapy for pneumonia

We read Claudine Blum and colleagues’ study (April 18, p 1511)1 with interest. We are concerned that selection bias might have occurred during recruitment, leading to a study population with relatively mild-to-moderate community-acquired pneumonia (CAP), which might not show the true benefits and disadvantages of corticosteroid treatment and could exclude a subpopulation who might benefit greatly from corticosteroids. The investigators did not discuss the low rate of recruitment (in 4·5 years and seven tertiary hospitals only 802 [27%] of 2911 identified patients were recruited).